{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/fungal-skin-infection-scalp/prescribing-information/oral-griseofulvin/","result":{"pageContext":{"chapter":{"id":"eb8ea077-2ef7-5dd1-b454-43ca5a07d5a0","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin","depth":2,"htmlHeader":"<!-- begin field fc79eb6a-d838-402b-97be-a8aa00dc9515 --><h2>Oral griseofulvin</h2><!-- end field fc79eb6a-d838-402b-97be-a8aa00dc9515 -->","summary":"","htmlStringContent":"<!-- begin item e3ff0777-16f2-46c1-a98c-a8aa00dc9391 --><!-- end item e3ff0777-16f2-46c1-a98c-a8aa00dc9391 -->","topic":{"id":"2366ecbc-4749-5ca6-8bc3-3873089df3da","topicId":"0fd8e2d0-69ae-41e6-b283-543453f673bc","topicName":"Fungal skin infection - scalp","slug":"fungal-skin-infection-scalp","lastRevised":"Last revised in April 2018","chapters":[{"id":"8a51d4c9-69eb-58f9-ac0b-38f666f1f848","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"97441633-de03-58fd-9e1b-bb42c2828337","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"7bc5a70d-2277-5bff-9951-bb0c0ab337ef","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"f9145ac8-339e-59bb-b8ad-25b709acdacb","slug":"changes","fullItemName":"Changes"},{"id":"d0c182d2-7ce4-57e0-9dee-362b0b530365","slug":"update","fullItemName":"Update"}]},{"id":"6f048cdd-1cbb-5611-a5e0-8361b221db8a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"599dbe6a-d7a3-5f91-91ed-4be709b1180c","slug":"goals","fullItemName":"Goals"},{"id":"84c3bfe1-6c40-57e4-a749-77a9946a89e3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ac49d0bf-50dc-5071-a82b-62723de01de5","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"60065f70-8af3-5f60-9dca-ff069607e2bc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"fba31ad2-44ba-5fe6-bf46-7345ab044a0e","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d12ccb71-eddd-5517-8749-1217ba0b4eb6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ba0c5ffb-2309-5d72-90e0-4c09ec2762ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a7a6e00a-8e02-5305-be1d-1aa4389187a5","slug":"definition","fullItemName":"Definition"},{"id":"a7f24440-b63f-56f4-8c94-3bb4b1877412","slug":"prevalence","fullItemName":"Prevalence"},{"id":"015c5679-e685-58cd-b557-2ed3559a9603","slug":"complications","fullItemName":"Complications"},{"id":"8fa3f79d-ba1c-5733-8306-100d8afeabfb","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fa2925a0-ec3e-5255-b9f9-7959141a2e82","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"b464e67b-56da-51d3-a0d4-4577dd9c24f7","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"4d8408bc-15aa-5151-a55a-b7849dcb8387","slug":"assessment","fullItemName":"Assessment"},{"id":"67ef57a0-32a1-5271-8ef9-7a7e9e1e5a24","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"05c0fb7d-20c2-5b68-9935-1d3c3f46f68d","fullItemName":"Management","slug":"management","subChapters":[{"id":"263ea5e0-37c2-539f-8fd6-e1218c2c16a1","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"b923eed5-33a1-596e-974f-5611050a47c7","slug":"oral-terbinafine","fullItemName":"Oral terbinafine"},{"id":"eb8ea077-2ef7-5dd1-b454-43ca5a07d5a0","slug":"oral-griseofulvin","fullItemName":"Oral griseofulvin"},{"id":"599d0b59-095a-52c5-8bd1-289c5e9c48af","slug":"oral-itraconazole","fullItemName":"Oral itraconazole"},{"id":"e6d4f0f1-7501-5b3f-9954-957d8152ffb7","slug":"topical-antifungals","fullItemName":"Topical antifungals"}]},{"id":"cc03af24-7789-56ce-978f-b905a9611cb5","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ce8e8c93-7919-5160-9ad5-965fcd16658f","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"e05609c9-c42a-5eec-b055-39a296c3e2ea","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e4f27b22-bcda-54f2-83f3-4ebf35f962ba","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0ce2862f-cdca-57b0-9998-9bc40799914a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"7e057656-6867-5510-95c7-019671326f4b","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"687c951d-457b-52b6-93f8-e38d5eafe6ed","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f17589e6-56a0-535c-aa03-0856855943bb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"2c583161-dd9d-5bf1-9fb1-a1395842cac9","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"23c84266-ebff-5038-9c4f-8b74009d915e","slug":"dosing-schedule","fullItemName":"Dosing schedule","depth":3,"htmlHeader":"<!-- begin field 235339f5-e4ee-439a-907b-a8c5015a7e9d --><h3>Dosing schedule</h3><!-- end field 235339f5-e4ee-439a-907b-a8c5015a7e9d -->","summary":"","htmlStringContent":"<!-- begin item e870c1de-643d-41a0-ad79-a8c5015a7de2 --><!-- begin field dadf76d2-1eec-4433-b429-a8c5015a7e9d --><p><strong>Griseofulvin is the only licensed oral antifungal agent for the treatment of fungal scalp infection in children in the UK.</strong></p><ul><li>For children aged 1 month to 11 years:<ul><li>Prescribe usual dose 10 mg/kg daily (maximum per dose 500 mg), increased if necessary to 20 mg/kg daily (maximum per dose 1 g), for severe infections.<ul><li>Reduce the dose when clinical response occurs; daily dose may be taken once daily or in divided doses.</li></ul></li></ul></li><li>For children aged 12–17 years:<ul><li>Prescribe 500 mg daily, increased if necessary to 1 g daily, for severe infections.<ul><li>Reduce the dose when clinical response occurs; daily dose may be taken once daily or in divided doses.</li></ul></li></ul></li><li>For adults, prescribe 1000 mg once a day or 500 mg twice a day for 4–8 weeks.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF for Children, 2017</a>] </p><!-- end field dadf76d2-1eec-4433-b429-a8c5015a7e9d --><!-- end item e870c1de-643d-41a0-ad79-a8c5015a7de2 -->","subChapters":[]},{"id":"ecb10e50-2496-58fe-8639-101a3e4770fa","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b9823d43-4377-4b8c-b500-a8aa00e1418e --><h3>Contraindications and cautions</h3><!-- end field b9823d43-4377-4b8c-b500-a8aa00e1418e -->","summary":"","htmlStringContent":"<!-- begin item 1a1b4f4d-f403-443f-8bce-a8aa00e140ad --><!-- begin field f5b2748f-c54e-43ef-bd3a-a8aa00e1418e --><ul><li><strong>Do not prescribe griseofulvin to people with:</strong><ul><li>Acute porphyria.</li><li>Severe liver disease.</li><li>Systemic lupus erythematosus — increased risk of exacerbation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF for Children, 2017</a>] </p><!-- end field f5b2748f-c54e-43ef-bd3a-a8aa00e1418e --><!-- end item 1a1b4f4d-f403-443f-8bce-a8aa00e140ad -->","subChapters":[]},{"id":"05ea6363-e8c1-5d5a-ac42-f807327434bc","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field ae139d62-dfd4-44a2-8dc8-a8aa00e158d9 --><h3>Adverse effects</h3><!-- end field ae139d62-dfd4-44a2-8dc8-a8aa00e158d9 -->","summary":"","htmlStringContent":"<!-- begin item d319f616-bda0-4e97-b550-a8aa00e157ce --><!-- begin field 09fffe67-ddcb-4c87-b9d7-a8aa00e158d9 --><ul><li><strong>Possible adverse effects of griseofulvin include:</strong><ul><li>Gastrointestinal — such as nausea, vomiting, diarrhoea, abdominal pain, dyspepsia, anorexia.<ul><li>Advise the person to take griseofulvin after a high-fat meal to increase systemic absorption and reduce the risk of adverse effects.</li></ul></li><li>Hepatobiliary — alteration in liver function tests (LFTs), intrahepatic cholestasis, and hepatitis.</li><li>Neuropsychiatric — headache, dizziness, confusion, taste disturbance, impaired co-ordination and hearing<strong>, </strong>peripheral neuropathy, sleep disturbances, agitation, and irritability.<ul><li>Advise the person that griseofulvin may enhance the effects of alcohol and impair the performance of skilled tasks, such as driving.</li></ul></li><li>Skin — rashes such as erythema multiforme, toxic epidermal necrolysis, photosensitivity, bullous reactions (including Lyell's syndrome), urticarial reactions.</li><li>Other — fatigue, leucopenia, neutropenia, anaemia (usually resolve on stopping treatment).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF for Children, 2017</a>] </p><!-- end field 09fffe67-ddcb-4c87-b9d7-a8aa00e158d9 --><!-- end item d319f616-bda0-4e97-b550-a8aa00e157ce -->","subChapters":[]},{"id":"d06734b9-6154-524e-ac6f-2c517a0736f3","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field f5774f32-4a10-4fd6-9239-a8aa00e17016 --><h3>Drug interactions</h3><!-- end field f5774f32-4a10-4fd6-9239-a8aa00e17016 -->","summary":"","htmlStringContent":"<!-- begin item 9008cdd7-3218-474e-8008-a8aa00e16f59 --><!-- begin field d421a9e0-09fe-4873-9d65-a8aa00e17016 --><p><strong>Possible drug interactions with griseofulvin include:</strong></p><ul><li>Alcohol — concurrent use of alcohol and griseofulvin may cause a disulfiram-like reaction (flushing, tachycardia). Warn people about the possibility of this reaction.</li><li>Oral contraceptives — the efficacy of oral contraceptives may be reduced with concurrent griseofulvin use. The clinical significance of this effect is unknown.<ul><li>The Faculty of Sexual and Reproductive Healthcare (FSRH) recommends avoiding use of combined oral contraceptives (COCs) and progestogen-only contraceptives (POPs), the progestogen-only implant, and ulipristal acetate, and using an alternative method of contraception when using griseofulvin, and within 28 days of stopping treatment.<ul><li>If a woman wishes to use the COC when taking griseofulvin, consider an increased ethinylestradiol dose (at least 50 micrograms) during treatment and for a further 28 days after stopping griseofulvin, with a continuous or tricycling regimen plus pill-free interval of four days.</li><li>See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-assessment/\">Contraception - assessment</a> for more information.</li></ul></li></ul></li><li>Warfarin — griseofulvin potentially decreases the efficacy of warfarin. Monitor the international normalized ratio (INR), and adjust the anticoagulant dose accordingly. </li><li>Phenobarbital — may result in a decreased plasma level of griseofulvin, leading to a reduction in efficacy.</li><li>Primidone — may result in a decreased plasma level of griseofulvin, leading to a reduction in efficacy.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">MHRA, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/fungal-skin-infection-scalp/references/\">FSRH, 2017</a>]</p><!-- end field d421a9e0-09fe-4873-9d65-a8aa00e17016 --><!-- end item 9008cdd7-3218-474e-8008-a8aa00e16f59 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}